Related coverage linked through entity extraction aliases.
Aug 11, 2026
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
Aug 10, 2026
Alnylam reported Q4 2025 adjusted EPS of $1.25, beating estimates, while revenue of $1.10 billion missed consensus despite 85% growth. Amvuttra sales surged 189% to $826.6 million. The stock fell 4.1% after the mixed results.
Apr 22, 2026
Roche's Elecsys pTau181 test received FDA clearance for primary care use, and its Elecsys ApoE4 test earned CE Mark approval. Despite these advances, Medicare does not cover Alzheimer's blood biomarker screenings before symptoms appear, prompting the bipartisan ASAP Act.
Jul 21, 2026
Roche's giredestrant plus palbociclib missed its primary endpoint in a phase 3 breast cancer trial. Numerical improvement was seen without statistical significance. Shares fell sharply; a second readout is due in 2027.
Jul 30, 2026
U.S. biotech IPOs have returned 55% on average this year, crushing the broader IPO market. Nvidia exited Recursion as ARK Invest bought shares, while Revolution Medicines gained 132% on strong pancreatic cancer data.
May 08, 2026
Market reports project growth in omics-based clinical trials, Asia digital PCR consumables, and multi-omic fluidic samplers. The clinical trials market is set to reach $47.78B by 2030; fluidic samplers grow to $2.76B by 2036.
Jul 10, 2026
AI is transforming cardiovascular medicine: $1.4B+ in investments, a new cardiac biomarker sensor, and stroke-imaging software in 2,500+ hospitals. FDA, EMA, and PMDA are opening clearer regulatory pathways.
Jul 29, 2026
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
Jun 17, 2026
FiberSense received CE marking for its optical CGM system with up to 28-day wear, while LifeScan partnered with i-SENS to launch the OneTouch Vita CGM and appointed a new CEO. Senseonics' year-long Eversense 365 implantable CGM is also detailed.
Aug 08, 2026
Roche stock trades steadily as group sales reach the mid-CHF 60 billion range. Q1 2025 revenue edged higher, and 2025 guidance points to low to mid single digit sales growth.
Aug 04, 2026
Hengrui Medicine won NMPA clearance for a Phase II NSCLC trial combining SHR-A2009 ADC with adebrelimab or EGFR-TKI, and with partner Kailera reported up to 12.1% weight loss in a Phase II obesity study of oral ribupatide. SHR-A2009 monotherapy NDA is under review for NSCLC, and cumulative R&D on SHR-A2009 has reached RMB 330 million.
Jul 30, 2026
Novartis AG is selling its 70.68% controlling stake in Novartis India to ChrysCapital for $175 million, triggering a mandatory open offer at INR 860.64 per share. Shares surged 20% as the Swiss drugmaker shifts investment to US manufacturing amid tariff risks.
Jul 27, 2026
Trump’s phased tariffs on medicines spur over $400 billion in US pharma investments. Indian generic makers face a 2028 deadline to adapt.
Jul 25, 2026
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
Jul 13, 2026
Cue Biopharma appointed Dominic Borie as chief medical officer and R&D head as it advances CUE-221 (Phase 2 data expected Q3 2026) and CUE-401 (Phase 1 start Q4 2026). He brings over 20 years of immunology and clinical development experience. The company recently raised $50M to support clinical development.
Jul 11, 2026
The GE HealthCare-Mayo MI-BET collaboration advances biomarker-guided prostate cancer therapy. The precision oncology market, valued at $122.6B in 2025, is projected to reach $317.2B by 2034, fueled by genomics and targeted treatments.
Jun 18, 2026
Ocular Therapeutix stock surged 30% in premarket trading as the company prepared to release topline Phase 3 data for AXPAXLI in wet AMD. The SOL-1 trial results will be presented at the Macula Society meeting later in February. The company plans to file for FDA approval using one-year data if results are favorable.
Jun 14, 2026
Switzerland will vote on June 14 on a proposal to cap its population at 10 million by 2050, which would restrict migration and potentially end EU free-movement agreements. Corporate leaders and business groups warn of severe labor shortages and economic damage. Polls show the vote is closely contested, with the population having grown rapidly in recent decades.
Jun 13, 2026
Teva Pharmaceuticals and Sanofi reported positive Phase 2b long-term extension results for duvakitug, a TL1A-targeting monoclonal antibody, showing durable efficacy over 44 weeks in ulcerative colitis and Crohn's disease patients. UC patients achieved up to 58% clinical remission and CD patients up to 55% endoscopic response at the higher dose.
Jun 11, 2026
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
